Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
VYNE Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $-5.00 Mil.
VYNE Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics EV-to-EBIT Related Terms
VYNE Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for VYNE Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VYNE Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VYNE Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where VYNE Therapeutics's EV-to-EBIT falls into.
VYNE Therapeutics's current Enterprise Value is $-21.02 Mil.
VYNE Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics (VYNE) has a EV-to-EBIT of 0.86 as of Aug. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on VYNE Therapeutics and its competitors. According to the industry distribution chart, VYNE Therapeutics ranks #69 out of 365 companies in the Biotechnology industry, placing it in the top 18.9%.
Is VYNE Therapeutics' EV-to-EBIT too high?
VYNE Therapeutics' current EV-to-EBIT is 0.86. The Biotechnology industry median EV-to-EBIT is 15.95. VYNE Therapeutics' value of 0.86 is 94.6% below this industry median. Based on the distribution chart, VYNE Therapeutics ranks #69 out of 365 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VYNE Therapeutics has a GF Score™ of 41/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does VYNE Therapeutics' EV-to-EBIT compare to NXTC and LPCN?
According to the Biotechnology industry distribution chart, VYNE Therapeutics ranks #69 out of 365 companies for EV-to-EBIT. This places VYNE Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.95. VYNE Therapeutics' value of 0.86 is 94.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VYNE Therapeutics's current EV-to-EBIT of 0.86 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on VYNE Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VYNE Therapeutics's current EV-to-EBIT is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VYNE Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, VYNE Therapeutics (VYNE) is currently considered Fairly Valued. The stock's GF Value™ is $30.63, compared to a current price of $27.86 — trading 9.1% below its estimated fair value. The current EV-to-EBIT is 0.86 and 94.6% below the Biotechnology industry median of 15.95. VYNE Therapeutics' overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For VYNE Therapeutics (VYNE), the current EV-to-EBIT is 0.86 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VYNE Therapeutics (VYNE) Overvalued in 2026?
Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be undervalued.
The current stock price of $27.86 is trading 9.1% below its estimated GF Value™ of $30.63.
GuruFocus considers VYNE Therapeutics to be Fairly Valued.
Key valuation signals for VYNE:
EV-to-EBIT: 0.86
GF Value™: $30.63 vs. price of $27.86 (9.1% below fair value)
Industry Position: 94.6% below the Biotechnology median (#69 of 365)
No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
41GF Score
Get the complete analysis for VYNE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VYNE has been successfully added to your 
